11 of 24
BACKNEXT
11. Gilead Sciences
Gilead Sciences
Fortune 500 rank: 444
2008 revenue: $5.3 billion
2008 total shareholder return: 11.1%

The No. 2 biotech on the Fortune 500 (after Amgen), Gilead is known for its top-selling HIV drugs, particularly the first single-pill HIV treatment. Its 11% gain in 2008 caps an impressive 5-year run - a return of more than 200%.

NEXT: General Mills
Last updated April 20 2009: 1:34 PM ET
2009 Fortune 500
Top 50
Top 50
Exxon Mobil pushes Wal-Mart aside to retake the No. 1 slot this year. Which other companies made the top 50 this year? More
They're hiring!
They're hiring!
As many big companies are announcing mass layoffs, these Fortune 100 employers have at least 150 openings each. More
The biggest losers
The biggest losers
Companies from AIG to United Airlines, from ConocoPhillips to Motorola lost billions of dollars last year. Who lost the most? More
Contact Us Closed Captioning Manage Cookies+ Site Map

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.